Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN®-Filo Ebola vaccine regimen: a phase 2 randomised clinical study in Europe (EBOVAC2) by Pollard, AJ, Launey, O, Lelievre, J-D, Lacabaratz, C, Gibani, M, Clutterbuck, E

IL-7 abrogates memory T regulatory cell functions by modulation of CD39/ATP axis in vitro and in vivo in HIV infected and non-infected patients by Younas M, Hue S, Surenaud M, Lacabaratz C, Guiguin A, Wiedman A, Becq S, Croughs T, Lelievre J, Levy Y

Vaccination with dendritic cells loaded with HIV-1 lipopeptides elicits broad T cell immunity and control of viral load in HIV infected patients by Levy Y, Thiébaut R, Montes M, Lacabaratz C, Sloan L, Perusat S, Harrod C, Boucherie C, Zurawski S, Richert L, Chêne G, Banchereau J, Palucka K

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical tr... by Barry, H, Mutua, G, Kibuuka, H, Anywaine, Z, Sirima, SB, Meda, N, Anzala, O, Eholie, S, Bétard, C, Richert, L, Lacabaratz, C, McElrath, MJ, de Rosa, S, Cohen, KW, Shukarev, G, Robinson, C, Gaddah, A, Heerwegh, D, Bockstal, V, Luhn, K, Leyssen, M, Douoguih, M, Thiébaut, R, Thiebaut, R